California-based biotech Cytokinetcs ( CYTK 4.56%) finished the trading week in style, as its stock price outperformed many ...

Investing.com -- Shares of Cytokinetics (NASDAQ: CYTK ), Incorporated (NASDAQ:CYTK) climbed 4.8% after the company announced that Sanofi (NASDAQ: SNY) will acquire exclusive rights to develop and ...

As Cytokinetics’ aficamten awaits approval decisions from regulators in the U.S. and China, Sanofi has picked up China rights ...

Cytokinetics (CYTK) announced that Sanofi (SNY) will acquire exclusive rights to develop and commercialize aficamten from Corxel ...

Cytokinetics, Inc.(CYTK), a late-stage, specialty cardiovascular biopharmaceutical company, Friday announced that French drug major ...

SOUTH SAN FRANCISCO, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CYTK) today announced that Sanofi will acquire ...

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Sanofi will acquire exclusive rights to develop and commercialize aficamten ...

Using the 2 Stage Free Cash Flow to Equity, Cytokinetics fair value estimate is US$48.61 With US$46.36 share price, Cytokinetics appears to be trading close to its estimated fair value ...

Cytokinetics, Incorporated (NASDAQ:CYTK – Get Free Report) has been given a consensus rating of “Moderate Buy” by the sixteen analysts that are currently covering the stock, Marketbeat reports. Four ...

It has been about a month since the last earnings report for Cytokinetics (CYTK). Shares have lost about 9.7% in that time frame, underperforming the S&P 500. Will the recent negative trend ...